Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial

BACKGROUND: Although highly active antiretroviral therapy (HAART) has dramatically decreased HIV-related morbidity and mortality, the associated costs, toxicities, and resistance risks make the potential delay of HAART initiation an attractive goal. Suppression of herpes simplex virus type 2 (HSV-2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Darrell HS, Raboud, Janet M, Kaul, Rupert, Grinsztejn, Beatriz, Cahn, Pedro, Walmsley, Sharon L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002348/
https://www.ncbi.nlm.nih.gov/pubmed/21106086
http://dx.doi.org/10.1186/1745-6215-11-113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002348/
https://www.ncbi.nlm.nih.gov/pubmed/21106086
http://dx.doi.org/10.1186/1745-6215-11-113

Ejemplares similares